Allan Klein, ACR 2021: Rilonacept RHAPSODY Trial in Recurrent Pericarditis

It was a pleasure to discuss with Prof. Allan Klein (Cleveland Clinic, Cleveland, OH, USA) the results from the phase 3, RHAPSODY trial (NCT03737110) investigating the once-weekly IL-1α/IL-1β trap, rilonacept, in patients with recurrent pericarditis.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract entitled ‘RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis’ (ABSTRACT NUMBER: 1454) was presented at the ACR Convergence, 3-9 November 2021.

Questions

1. What is the rationale for the use of rilonacept in the treatment of patients with recurrent pericarditis? (0:12)
2. What were the aims, design, and inclusion criteria of the RHAPSODY trial? (0:57)
3. What were the findings from the study? (2:13)
4. What do these results mean for patients and clinical practice? (3:22)

Disclosures: Prof. Allan Klein has acted as an advisor for Kiniska, Sobi and Pfizer, and received grant/ research support from Kiniksa.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.